# Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy

> **NCT03267381** · — · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 37 (actual)

## Conditions studied

- Melanoma

## Interventions

- **OTHER:** Blood draw (before surgery)
- **OTHER:** Blood draw (every 3 months)
- **OTHER:** Blood draw (at diagnosis)

## Key facts

- **NCT ID:** NCT03267381
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-03
- **Primary completion:** 2023-09-27
- **Final completion:** 2023-09-27
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03267381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03267381, "Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03267381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*